Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer. If you have been diagnosed with NSCLC, your health care provider may test your cancer to see if it has certain genetic ...
Results showed a statistically significant improvement in progression free survival in patients treated with amivantamab with carboplatin + pemetrexed compared with those who received carboplatin + ...
CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. Lung cancer research has recognized the role of EGFR ...
In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat non–small cell lung cancer (NSCLC). Continuing our discussion with Martin ...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (ORIC), a clinical stage oncology company focused on developing treatments that address ...
In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%. The Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy ® (sunvozertinib) for ...
The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer ...
The agency is slated to decide whether to grant accelerated approval to the drug for treating NSCLC patients with EGFR exon 20 insertion mutations by February 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results